{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T14:35:48Z","timestamp":1768833348054,"version":"3.49.0"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To synthesize pharmacoeconomic evidence of prevention and treatment of venous thromboembolism (VTE) in cancer patients with direct oral anticoagulants (DOACs) and evaluate the quality of the studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>PubMed, Embase, Scopus, the Cochrane Library, the Center for Reviews and Dissemination Database, the Health Technology Assessment Database, and the China National Knowledge Infrastructure Database were searched to collect economic evaluations. The search covered publications from their inception until June 13, 2024. Study selection was conducted independently by two researchers, with discrepancies resolved through discussion. The quality of the studies were assessed using the Consolidated Health Economic Evaluation Reporting Standards 2022 checklist, and the basic characteristics of the included studies were summarized descriptively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 15 studies were included, covering different income level countries: the United States, Spain, China, the Netherlands, Canada, and Brazil. Economic evaluation results for prevention strategies varied in different countries. The baseline VTE incidence and drug costs will determine whether DOACs are worthwhile. For the treatment of VTE in cancer patients, DOACs were found to be more cost-effective compared to low molecular weight heparins (LMWHs) and warfarin, though the incremental cost-effectiveness ratio varied significantly across countries. However, there is still a lack of pharmacoeconomic studies based on direct evidence on which DOAC to choose for VTE treatment in cancer patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The cost-effectiveness of DOACs for VTE in cancer patients has been proven. Further research is needed to determine the best choice of DOAC. Thromboprophylaxis in all cancer patients is not recommended. It is still necessary for clinicians to evaluate the risk of VTE. Pharmacoeconomic study results are significantly influenced by the drug costs, patient preferences, and income levels of different countries and regions. Economic decisions should be made according to the specific national background.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2025.1498692","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T05:31:37Z","timestamp":1745818297000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacoeconomic evaluation of direct oral anticoagulants for cancer-associated thrombosis: a systematic review"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiaoyan","family":"You","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiali","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"11795549231220297","DOI":"10.1177\/11795549231220297","article-title":"Cancer-associated thrombosis: epidemiology, pathophysiological mechanisms, treatment, and risk assessment","volume":"17","author":"Pavlovic","year":"2023","journal-title":"Clin Med Insights Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"180119","DOI":"10.1183\/16000617.0119-2018","article-title":"Cancer-associated thrombosis: the when, how and why","volume":"28","author":"Fernandes","year":"2019","journal-title":"Eur Respir Rev"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/sj.neo.7900263","article-title":"The hypercoagulable state of malignancy: pathogenesis and current debate","volume":"4","author":"Caine","year":"2002","journal-title":"Neoplasia"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1160\/TH16-08-0615","article-title":"Cancer-associated venous thromboembolism: burden, mechanisms, and management","volume":"117","author":"Ay","year":"2017","journal-title":"Thromb Haemost"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.thromres.2016.01.002","article-title":"Risk factors for incident venous thromboembolism in active cancer patients: a population based case-control study","volume":"139","author":"Ashrani","year":"2016","journal-title":"Thromb Res"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/s12885-015-1200-6","article-title":"Epidemiology, clinical profile and treatment patterns of venous thromboembolism in cancer patients in Taiwan: a population-based study","volume":"15","author":"Chew","year":"2015","journal-title":"BMC Cancer"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s11239-020-02180-x","article-title":"GARFIELD-VTE investigators. Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE","volume":"50","author":"Weitz","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/cncr.25714","article-title":"Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis","volume":"117","author":"Lyman","year":"2011","journal-title":"Cancer"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2147\/CEOR.S39964","article-title":"Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States","volume":"5","author":"Khorana","year":"2013","journal-title":"Clinicoecon Outcomes Res"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1080\/13696998.2021.1948681","article-title":"Healthcare costs of patients with cancer stratified by Khorana score risk levels","volume":"24","author":"Khorana","year":"2021","journal-title":"J Med Econ"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"Key","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"ESMO guidelines committee. Venous thromboembolism in cancer patients: ESMO clinical practice guideline","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.6004\/jnccn.2021.0047","article-title":"Cancer-associated venous thromboembolic disease, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Streiff","year":"2021","journal-title":"J Natl Compr Cancer Netw"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","article-title":"Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"21","author":"Kumar","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.jval.2022.03.002","article-title":"Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s11239-019-01903-z","article-title":"Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosis","volume":"48","author":"Connell","year":"2019","journal-title":"J Thromb Thrombolysis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.thromres.2019.05.012","article-title":"Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States","volume":"180","author":"Li","year":"2019","journal-title":"Thromb Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.ygyno.2020.07.096","article-title":"Cost-effectiveness of apixaban for prevention of venous thromboembolic events in patients after gynecologic cancer surgery","volume":"159","author":"Glickman","year":"2020","journal-title":"Gynecol Oncol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1002\/cncr.32724","article-title":"Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States","volume":"126","author":"Li","year":"2020","journal-title":"Cancer"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e1075","DOI":"10.1200\/OP.20.00783","article-title":"Cost-effectiveness of venous thromboembolism prophylaxis during neoadjuvant chemotherapy for ovarian cancer","volume":"17","author":"Ryan","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s40261-022-01217-8","article-title":"Cost-utility analysis comparing direct oral anticoagulant and low molecular weight heparin therapies for secondary prevention of cancer-associated thrombosis","volume":"42","author":"Shin","year":"2022","journal-title":"Clin Drug Investig"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1136\/ijgc-2023-004922","article-title":"Prophylactic anticoagulation after minimally invasive hysterectomy for endometrial cancer: a cost-effectiveness analysis","volume":"33","author":"Bell","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/L23-0345","article-title":"Anticoagulant therapy for cancer-associated thrombosis: a cost-effectiveness analysis","volume":"176","author":"Gulati","year":"2023","journal-title":"Ann Intern Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1080\/13696998.2022.2087998","article-title":"Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain","volume":"25","author":"Mu\u00f1oz","year":"2022","journal-title":"J Med Econ"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1080\/13696998.2023.2248839","article-title":"Cost-effectiveness of apixaban and rivaroxaban in thromboprophylaxis of cancer patients treated with chemotherapy in Spain","volume":"26","author":"Mu\u00f1oz","year":"2023","journal-title":"J Med Econ"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e039057","DOI":"10.1136\/bmjopen-2020-039057","article-title":"Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism","volume":"10","author":"de Jong","year":"2020","journal-title":"BMJ Open"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"E1551","DOI":"10.1503\/cmaj.210523","article-title":"Cost-utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer","volume":"193","author":"Kimpton","year":"2021","journal-title":"CMAJ"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.thromres.2020.08.014","article-title":"Cost-effectiveness of edoxaban vs low-molecular-weight heparin and warfarin for cancer-associated thrombosis in Brazil","volume":"196","author":"Lopes","year":"2020","journal-title":"Thromb Res"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s40261-020-00926-2","article-title":"New oral anticoagulants for thromboprophylaxis in patients with cancer receiving chemotherapy: an economic evaluation in a Chinese setting","volume":"40","author":"Du","year":"2020","journal-title":"Clin Drug Investig"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12959-021-00319-1","article-title":"Direct oral anticoagulants versus low molecular weight heparins for the treatment of cancer-associated thrombosis: a cost-effectiveness analysis","volume":"19","author":"Wumaier","year":"2021","journal-title":"Thromb J"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"AVERT investigators. Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"CASSINI investigators. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.15518","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1002\/onco.13569","article-title":"Prediction and prevention of cancer-associated thromboembolism","volume":"26","author":"Khorana","year":"2021","journal-title":"Oncologist"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.thromres.2018.02.144","article-title":"Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis","volume":"173","author":"Li","year":"2019","journal-title":"Thromb Res"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/16078454.2020.1719726","article-title":"Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer","volume":"25","author":"Wang","year":"2020","journal-title":"Hematology"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1081\/copd-200052090","article-title":"The minimally clinically important difference in generic utility-based measures","volume":"2","author":"Kaplan","year":"2005","journal-title":"COPD"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1200\/JCO.22.00255","article-title":"A clinical-genetic risk score for predicting cancer-associated venous thromboembolism: a development and validation study involving two independent prospective cohorts","volume":"41","author":"Mu\u00f1oz","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Hokusai VTE cancer investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J Thromb Haemost"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Caravaggio investigators. Apixaban for the treatment of venous thromboembolism associated with Cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s11239-020-02151-2","article-title":"Network meta-analysis of anticoagulation strategies for venous thromboembolism in patients with cancer","volume":"51","author":"Ueyama","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"ref45","year":"2019"},{"key":"ref46","year":"2024"},{"key":"ref47","year":"2024"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"ISPOR health economic evaluation publication guidelines-CHEERS good reporting practices task force. Consolidated health economic evaluation reporting standards (CHEERS)--explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"572569","DOI":"10.3389\/fphar.2020.572569","article-title":"Pharmacoeconomic evaluation of cancer biosimilars worldwide: a systematic review","volume":"11","author":"Huang","year":"2020","journal-title":"Front Pharmacol"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1498692\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T05:31:39Z","timestamp":1745818299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1498692\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":49,"alternative-id":["10.3389\/fpubh.2025.1498692"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1498692","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"article-number":"1498692"}}